This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kwan P and Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342: 314–319
Selwa LM et al. (2003) Long-term outcome of nonsurgical candidates with medically refractory localization-related epilepsy. Epilepsia 44: 1568–1572
Sillanpaa M and Schmidt D (2006) Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 129: 617–624
Berg AT et al. (2006) How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol 60: 73–79
Acknowledgements
The synopsis was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
In the last 12 months, Dr French has received <US$10,000 in speaking/consulting fees from Eisai, Valeant/Schwarz, Spherics, Johnson & Johnson and Astra-Zeneca.
Dr French has also provided consulting services to UCB, Marinus, Johnson & Johnson, Teva, Schwarz, Valeant, Shire, Intranasal, Jazz and Eisai. She serves as chair of the data safety monitoring board for a study sponsored by Johnson & Johnson. Over the past year, Dr French has provided these services as an agent of the nonprofit organization Epilepsy Therapy Development Project. The Epilepsy Therapy Development Project contributes a fixed amount to Dr French's salary for this and other services, including chairing their scientific advisory board and grant review. The amount of contribution is not linked to the amount of consulting activity.
Twenty percent of Dr French's salary derives from work on behalf of FACES (Finding A Cure for Epilepsy and Seizures), a nonprofit organization.
Dr French has been site principal investigator on studies of brivaracetam (UCB), RWJ-333369 (Johnson & Johnson), selectracetam (UCB), talampanel (Ivax), lacosamide (Schwarz Pharma), retigabine (Valeant), rufinamide (Eisai) and the thalamic stimulator (Medtronics). She is national principal investigator for an ongoing study of rufinamide, retigabine and the vagus nerve stimulator (Cyberonics).
Rights and permissions
About this article
Cite this article
French, J. Can drug regimen changes prevent seizures in patients with apparently drug-resistant epilepsy?. Nat Rev Neurol 3, 364–365 (2007). https://doi.org/10.1038/ncpneuro0500
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0500